These findings provide some insights into how patients carrying typical mutations could be most efficiently treated, why patients present side effects due to non-specific inhibitory effects of high concentrations of osimertinib on cells without EGFR mutations, and how to design new TKIs for cancers carrying triply mutated T790M/C797S/L858R EGFR. Here, EGFR is linked to cancer.